Antiphospholipid syndrome in cardiovascular disease and cancer

Author:

Pessach Ilias1ORCID,Kyriakou Elias2,Kalampokas Emmanouil3ORCID,Kalampokas Theodoros4ORCID,Bitsani Aikaterini5ORCID,Kotsianidis Ioannis6ORCID

Affiliation:

1. Hematology Department Athens Medical Center Athens Greece

2. Laboratory of Hematology and Blood Bank Unit, National and Kapodistrian University of Athens, Medical School "Attikon" University General Hospital Athens Greece

3. Unit of Gynecologic Oncology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School National and Kapodistrian University of Athens Athens Greece

4. Unit of Obstetrics and Gynecology, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School National and Kapodistrian University of Athens Athens Greece

5. First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School National and Kapodistrian University of Athens Athens Greece

6. Department of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis Greece

Abstract

AbstractAntiphospholipid syndrome is an autoimmune disorder which is characterized by the presence of heterogeneous antiphospholipid antibodies. There is an evidence on antiphospholipid (aPL) antibodies related to thromboembolic events in cancer patients. In fact, the thrombotic complications in patients with malignancy occur at a rather high frequency, compared to other risk factors. In parallel with standard therapies available, there is need of case‐by‐case monitoring of each patient and the introduction of new therapies and need for more clinical trials which will address many questions for the optimal management of patients. This paper presents a basic review of the literature on the aPL antibodies associated with cardiovascular disease and cancer, as well as its complications, which are reported so far in the bibliography.

Publisher

Wiley

Subject

Hematology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3